Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Nerve Block of the Vastus Medialis and Anterior Obturator Branch in Anterior Cruciate Ligament Reconstruction With DIDT Graft (RECUP-NVM)

The goal of this randomized clinical trial is to evaluate whether a targeted regional anesthesia strategy combining an adductor canal block, a nerve to the vastus medialis (NVM) block, an anterior obturator nerve branch block, and an iPACK block improves postoperative recovery in patients undergoing anterior cruciate ligament (ACL) reconstruction using a hamstring tendon (semitendinosus and gracilis; DIDT) graft, compared with the standard analgesic protocol used in participating centres, consisting of a femoral nerve block combined with an iPACK block.

The main question the study aims to answer is whether this targeted combination of nerve blocks, compared with the standard femoral nerve block plus iPACK regimen, improves the quality of postoperative recovery, as measured by the Quality of Recovery-15 (QoR-15) score at 24 hours after surgery.

The study hypothesis is that the targeted adductor canal + NVM + anterior obturator branch + iPACK strategy will significantly improve postoperative recovery quality at 24 hours compared with the standard femoral nerve block + iPACK protocol, with an expected improvement of at least 8 points on the QoR-15 score. This 8-point difference represents the minimal clinically important difference (MCID) for this questionnaire (Léger et al., 2020). The QoR-15 is a validated global recovery assessment tool, available in French, and sensitive to variations in recovery quality in outpatient orthopedic surgery (Nakase et al., 2021). An improvement of at least 8 points at 24 hours would therefore indicate a clinically meaningful benefit from the patient's perspective.

The study will also assess:

  • Postoperative pain at rest and during mobilization.
  • Opioid consumption during the first 48 hours after surgery.
  • Incidence of postoperative nausea and vomiting.
  • Time to first ambulation.
  • Postoperative thigh edema.
  • Neuromuscular recovery of the thigh.
  • Patient satisfaction with analgesic management.
  • Adverse events related to regional anesthesia.

Participants will be randomly assigned to one of two treatment groups. All participants will undergo ACL reconstruction with a DIDT graft. Participants in the comparator group will receive a femoral nerve block combined with an iPACK block. Participants in the intervention group will receive a targeted regional anesthesia strategy combining an adductor canal block, a nerve to the vastus medialis (NVM) block, an anterior branch of the obturator nerve block, and an iPACK block.

The planned volumes and doses for each block in the two randomized strategies are detailed as follows: Compared with the control group, which receives a femoral nerve block with 15 mL and an iPACK block with 20 mL of ropivacaine 0.35% (total volume: 35 mL; total dose: 122.5 mg), the intervention group receives an adductor canal block with 10 mL, a nerve to the vastus medialis block with 5 mL, an anterior branch of the obturator nerve block with 6 mL, and an iPACK block with 20 mL of ropivacaine 0.35% (total volume: 41 mL; total dose: 143.5 mg). Thus, the intervention group involves two additional nerve block targets and an additional 6 mL of ropivacaine, corresponding to an additional dose of 21 mg (+17.1%) compared with the control group. The cumulative dose will be checked against the patient-specific safety limits before performing the blocks. Patients in whom the blocks cannot be safely performed within these limits will not be included.

Postoperative assessments will include pain scores, QoR-15 questionnaires, opioid consumption, nausea and vomiting, thigh measurements, and neuromuscular function assessments during the first 48 hours after surgery. Patient satisfaction and safety outcomes will also be assessed during follow-up.

The primary outcome will compare the QoR-15 score at 24 hours between the two groups, with an 8-point difference considered clinically meaningful.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Estimé)

108

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 60 ans (Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Adult patients aged 18 to 60 years.
  • Patients with a primary anterior cruciate ligament (ACL) injury.
  • Patients scheduled for ACL reconstruction using a DIDT graft under general anesthesia.
  • Patients managed as ambulatory surgery or short stay.
  • Patients who understand the validated French version of the QoR-15 questionnaire.
  • Patients who have given written informed consent to participate in the study.
  • Patients affiliated with or beneficiaries of a social security system.

Exclusion Criteria:

  • Patients with a body weight below 50 kg, as the planned cumulative ropivacaine dose could exceed the safety limit of 3 mg/kg.
  • Patients with allergy to local anesthetics or a contraindication to peripheral nerve blocks.
  • Patients with lower-limb neuropathy.
  • Patients with coagulation disorders or on major anticoagulation.
  • Patients with chronic pain requiring more than 30 mg morphine-equivalents per day.
  • Patients undergoing revision ACL reconstruction or a major combined surgical procedure.
  • Pregnant women.
  • Patients unable to complete the questionnaires or who refuse to participate.
  • Pregnant women or women who may be pregnant (of childbearing potential without effective contraception) or who are breastfeeding.
  • Protected adults: patients under guardianship, curatorship or other legal protection, deprived of liberty, or unable to provide informed consent.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Adductor Canal + iPACK + NVM and Anterior Obturator Nerve Blocks

Participants will undergo anterior cruciate ligament reconstruction using a semitendinosus and gracilis (DIDT) graft. They will receive a targeted regional anesthesia protocol consisting of an adductor canal block, a nerve to the vastus medialis (NVM) block, an iPACK block, and a block of the anterior branch of the obturator nerve.

Ultrasound-guided infiltration between the popliteal artery and the posterior capsule of the knee (iPACK) administered as part of the regional anesthesia protocol.

Ultrasound-guided nerve block targeting the nerve to the vastus medialis (NVM), administered in addition to theadductor canal and iPACK blocks in the experimental arm.

Ultrasound-guided block of the anterior branch of the obturator nerve, administered in addition to the adductor canal and iPACK blocks in the experimental arm.

Ultrasound-guided adductor canal block administered as part of the targeted regional anesthesia protocol for ACL reconstruction in the experimental arm.

Comparateur actif: Femoral + iPACK Nerve Blocks

Participants will undergo anterior cruciate ligament reconstruction using a semitendinosus and gracilis (DIDT) graft. They will receive the standard regional anesthesia protocol consisting of a femoral nerve block and an iPACK block, without additional nerve blocks of the nerve to the vastus medialis (NVM) or anterior branch of the obturator nerve.

Ultrasound-guided infiltration between the popliteal artery and the posterior capsule of the knee (iPACK) administered as part of the regional anesthesia protocol.

Ultrasound-guided femoral nerve block administered as part of the standard regional anesthesia protocol for ACL reconstruction.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Quality of Recovery (QoR-15) Score
Délai: Baseline (preoperatively, before regional anesthesia) and 24 hours after surgery

The quality of postoperative recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire. The QoR-15 score ranges from 0 to 150, with higher scores indicating better quality of recovery. The primary analysis will compare the change in QoR-15 score from baseline to 24 hours postoperatively between the experimental and active comparator groups. An 8-point difference between groups is considered the minimal clinically important difference.

Baseline (preoperatively, before regional anesthesia) and 24 hours after surgery

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Postoperative Pain
Délai: 6, 24, and 48 hours after surgery

Pain intensity will be assessed using the Numeric Rating Scale (NRS), both at rest and during mobilization. The NRS ranges from 0 (no pain) to 10 (worst pain imaginable).

6, 24, and 48 hours after surgery
Postoperative Opioid Consumption
Délai: 24 and 48 hours after surgery

Total opioid consumption will be recorded and converted to oral morphine equivalents (OME).

24 and 48 hours after surgery
Postoperative Nausea and Vomiting
Délai: 24 and 48 hours after surgery

The incidence of postoperative nausea and vomiting (PONV) will be recorded.

24 and 48 hours after surgery
Time to ambulation
Délai: Day 0 (postoperative)

Time from completion of surgery to first postoperative ambulation will be recorded.

Day 0 (postoperative)
Postoperative Thigh Edema
Délai: Day 0 and Day 1 after surgery

Postoperative changes in thigh circumference will be measured at three standardized locations: 15 cm above the superior pole of the patella, at the level of the patellar apex, and 10 cm below the patellar apex.

Day 0 and Day 1 after surgery
Postoperative Neuromuscular Recovery of the Thigh
Délai: Day 0 and Day 1 after surgery

Neuromuscular recovery will be assessed using the Medical Research Council (MRC) scale, ranging from 0 (no muscle contraction) to 5 (normal muscle strength), across four motor tests: isometric heel press into the mattress, flattening of the popliteal fossa against the mattress, sliding knee flexion/extension, and straight-leg raise at 30 degrees.

Day 0 and Day 1 after surgery
Adverse Events Related to Regional Anesthesia
Délai: Day 0

Adverse events related to locoregional anesthesia will be recorded, including signs of local anesthetic systemic toxicity (LAST) and persistent paresthesia.

Day 0
Patient Satisfaction With Analgesic Management
Délai: 1 month after surgery

Patient satisfaction with postoperative analgesic management will be assessed using a 5-point Likert scale ranging from 1 (Very dissatisfied) to 5 (Very satisfied). Higher scores indicate greater patient satisfaction and a better outcome.

1 month after surgery

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Yoann ELMALEH, Hôpital Privé Claude Galien

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

15 novembre 2026

Achèvement primaire (Estimé)

15 novembre 2027

Achèvement de l'étude (Estimé)

15 novembre 2027

Dates d'inscription aux études

Première soumission

30 octobre 2026

Première soumission répondant aux critères de contrôle qualité

30 octobre 2026

Première publication (Réel)

5 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

6 novembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • COS-RGDS-2025-12-028-P-ELMALEH
  • 2026-A01040-51 (Autre identifiant: ID-RCB)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .